Cicatrix Clinical Trial
Official title:
A Double-Blind, Placebo-Controlled, Randomised Dose Ranging Trial to Investigate the Efficacy of Two Different Dosing Regimens of Avotermin (Juvista) in the Improvement of Scar Appearance When Applied to Approximated Wound Margins in Healthy Volunteers.
This is a single-centre, double-blind, Placebo-controlled, randomised trial. Trial subjects
received four 1cm incisional wounds on the inner aspect of each upper arm (eight in total),
giving four pairs of anatomically matched wound sites per subject. Each subject acted as
their own control. One site from each anatomical wound pair was randomly treated with
intradermally administered avotermin (Juvista:100μL per linear cm of wound site
pre-operatively and 100μL per linear cm of wound margin post-wounding on Day 0 or Day 1,
400μL per wound site) while the second site was a paired control, treated with Placebo
(100μL per linear cm of wound site pre-operatively and 100μL per linear cm of wound margin
post-wounding on Day 0 or Day 1, 400μL per wound site). Wound margins for injection were
defined as extending 0.5cm from either end of the incision. Four doses of avotermin
(Juvista) were administered to each subject: 5ng, 50ng, 200ng and 500ng/100μL per linear cm;
one dose to one wound site per anatomically matched pair of wounds. The second wound site
from each anatomically matched pair of wounds was dosed with placebo. Allocation of
treatment to wound-site pairs was randomised and double blinded.
Primary objective To determine the optimal concentration and dose regimen of Juvista for the
improvement of the resultant scar when applied to the approximated wound margins of male and
female subjects following surgical incisions.
Secondary objective To assess the safety and tolerance of Juvista when applied to the
approximated wound margins of male and female subjects following surgical incisions.
Status | Completed |
Enrollment | 78 |
Est. completion date | August 2007 |
Est. primary completion date | August 2007 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Males and females aged 18-85 years who have given written informed consent. - Subjects with a body mass index within 15-35 kg/m2 (Quetelet's index). Exclusion Criteria: - Subjects with history or evidence of keloid scarring. - Subjects with tattoos or previous scars within 3cm of the area to be incised. - Subjects who had surgery in the area to be incised within one year of the first dosing day. - Subjects with history of a bleeding disorder or who were receiving anti-coagulant or anti-platelet therapy. - Subjects with evidence of any past or present clinically significant disease that may affect the endpoints of the trial. - Subjects with a clinically significant skin disorder that was chronic or currently active. - Subjects with any clinically significant medical condition or history that would impair wound healing. - Subjects with history of hypersensitivity to any of the drugs or dressings used in this trial. - Subjects taking, or who have taken, any investigational product or who had participated in a clinical trial in the three months prior to first trial dose administration. - Subjects taking regular, continuous, oral corticosteroid therapy. - Subjects undergoing investigations or changes in management for an existing medical condition. - Subjects with a history of drug abuse, or with a positive drugs of abuse test for cocaine, amphetamines, methamphetamines, opiates or benzodiazepines during the screening period. - Subjects who, in the opinion of the investigator, were unlikely to complete the trial for whatever reason. - Subjects who had any clinically significant neurological impairment or disease. - Subjects with any active infection. - Subjects who are pregnant or lactating. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Clinical Trials Unit, Renovo | Manchester |
Lead Sponsor | Collaborator |
---|---|
Renovo |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine the optimal concentration and dose regimen of avotermim (Juvista) for the improvement of the resultant scar when applied to the approximated wound margins of male and female subjects following surgical incisions. | Post surgery: week 6 to Month 7 | No | |
Secondary | To assess the safety and tolerance of avotermin (Juvista) when applied to the approximated wound margins of male and female subjects following surgical incisions. | Day 0 (surgery) to Month 7 post surgery | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02645773 -
Early Intervention With Non-ablative Fractional Laser to Reduce Cutaneous Scarring
|
N/A | |
Completed |
NCT02672956 -
Comparison of Different Umbilical Port Entry Techniques in Terms of Cosmetic Results
|
N/A | |
Completed |
NCT00847795 -
Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.
|
Phase 1/Phase 2 | |
Completed |
NCT00977951 -
Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03213548 -
Aesthetic and Functional Results of Alar Base Modifications in Rhinoplasty
|
N/A | |
Recruiting |
NCT05377723 -
Abdominal Scar Improvement in Microsurgical Breast Reconstruction
|
N/A | |
Active, not recruiting |
NCT01976260 -
A Pilot Study Testing Fractional Radiofrequency Versus Fractional Photothermolysis for the Treatment of Acne Scars
|
N/A | |
Terminated |
NCT00432328 -
Juvista (Avotermin) in Breast Reduction Surgery Scars
|
Phase 2 | |
Completed |
NCT00594581 -
Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males
|
Phase 2 | |
Completed |
NCT00984503 -
Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites
|
Phase 2 | |
Recruiting |
NCT04420442 -
Scar Resection and Reconstruction With Integra and Split Skin Grafts in Patients With Non-Suicidal Self-Inflicted Scars
|
N/A | |
Completed |
NCT02772289 -
Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars
|
Phase 2 | |
Completed |
NCT00430326 -
Juvista (Avotermin) in Scars Following Varicose Vein Removal
|
Phase 2 | |
Completed |
NCT00847925 -
Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects
|
Phase 1/Phase 2 | |
Recruiting |
NCT05787171 -
Three Sutures With Different Absorption Rates for Lower Abdominal Incision
|
N/A | |
Completed |
NCT02985151 -
Interventional Study to Evaluate the Appearance of Surgical Scars After Laser Therapy
|
N/A | |
Completed |
NCT02340325 -
FS2 Safety and Tolerability Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT00432211 -
Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.
|
Phase 2 | |
Completed |
NCT00978302 -
Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)
|
Phase 1 | |
Withdrawn |
NCT04034615 -
The Long-term Effect of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars
|
Phase 2 |